Feb. 19 at 10:10 PM
The team at B2i Digital welcomes Phio Pharmaceuticals Corp. (NASDAQ:
$PHIO ) as a new Featured Company. A dedicated company profile will be available soon at https://b2idigital.com/featured-companies.
Phio is a clinical-stage biopharmaceutical company advancing a differentiated approach to immuno-oncology. The company’s proprietary INTASYL siRNA gene-silencing platform is designed to silence specific genes involved in immune suppression, with the goal of enhancing the body’s natural immune response against cancer.
Its lead program, PH-762, is designed as an intratumoral therapy, meaning the compound is injected directly into the tumor. PH-762 targets the PD-1 gene, which plays a central role in immune checkpoint regulation. By silencing PD-1 locally within the tumor microenvironment, Phio aims to reactivate tumor-infiltrating immune cells and strengthen anti-tumor activity. PH-762 is currently being studied in cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
Phio’s second candidate, PH-894, targets the BRD4 gene and is being developed for potential use across a broader range of solid tumors, including melanoma, head and neck cancers, and hepatocellular carcinoma. Both programs leverage the company’s self-delivering INTASYL platform, which is designed to avoid the need for complex delivery systems.
Today, Phio announced leadership changes designed to support the next stage of development for PH-762 and continued advancement of PH-894. Lisa Carson was promoted to Chief Financial Officer, Jennifer Phillips, Pharm.D., was elevated to Senior Vice President, Regulatory and Corporate Affairs, and Kimberly Man joined the company as Vice President of Program Development and Strategic Planning.
CEO Robert Bitterman commented:
“Upcoming regulatory discussions and clinical milestones demand a team built for follow-through. These appointments strengthen finance and regulatory leadership to support PH-762 as it moves into its next stage, while we continue work on PH-894. Our focus is delivering the next set of milestones with discipline and consistency.”
The leadership update comes as the Phase 1b trial for PH-762 has completed its treatment and excision phase. In the Phase 1b study, designed for up to 24 patients, a total of 22 patients with cutaneous carcinomas completed treatment in the Phase 1b trial and underwent excision of the treated lesional site. Among the 20 patients with cSCC, 13 patients were classified as pathologic responders, including 9 patients with complete response (100% clearance), 2 patients with major/near clear response (greater than 90% clearance), and 2 patients with partial response (greater than 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response. Seven cSCC patients and one melanoma patient had responses of less than 50%, however, none of the patients experienced a progression of the disease.
With a focused pipeline, clear clinical milestones, and a strengthened leadership team aligned with upcoming regulatory engagement, Phio is positioning itself for its next stage of development.
For the full press release, visit:
https://phiopharma.com/phio-pharmaceuticals-aligns-leadership-team-to-support-next-stage-development-of-ph-762-and-advancement-of-ph-894/.
To learn more about Phio Pharmaceuticals Corp., visit www.phiopharma.com. For investor inquiries, contact Jennifer Phillips at
[email protected].
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
$PHIO $ONCOLOGY $PD1 $CANCER.X
$CLINICALTRIALS $BIOTECH $SMALLCAP